ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1388	National Cancer Institute	Html	en	Neuroblastoma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of childhood neuroblastoma.	neuroblastoma 0.976116 childhood cancer neuroblastoma 0.551793 major familial neuroblastoma 0.521543 neuroblastoma progression 0.496843 unresectable/disseminated neuroblastoma 0.495818 Neuroblastoma Study Group 0.537536 intermediate-risk neuroblastoma patients 0.580486 neuroblastoma molecular diagnostics 0.511987 hereditary neuroblastoma 0.561905 intermediate-risk neuroblastoma group 0.584332 low-risk neuroblastoma susceptibility 0.521417 neuroblastoma identifies chromothripsis 0.508284 neuroblastoma risk group 0.724371 low-risk neuroblastoma 0.617352 High-risk neuroblastoma tumors 0.54129 high-risk neuroblastoma 0.745428 neuroblastoma section 0.536455 neuroblastoma SNP association 0.525331 stage IV-S neuroblastoma 0.494981 neuroblastoma cell 0.546055 Neuroblastoma Pathology Committee 0.5037 et al. 0.867573 Neuroblastoma Pathology Classification 0.578039 neuroblastoma tumors 0.563844 stage iv neuroblastoma 0.527215	diagnostic neuroblastoma samples. 0.552115 international neuroblastoma 0.731336 international neuroblastoma staging 0.561855 neuroblastoma cases 0.533897 PUBMED Abstract 0.580731 multifocal neuroblastoma 0.525099 neuroblastoma cells 0.534711 aggressive MYC-driven neuroblastoma 0.504084 Pediatr Blood Cancer 0.580995 Oncology Group study 0.606704 Italian Neuroblastoma group 0.510786 international neuroblastoma risk 0.640282 high-risk neuroblastoma group 0.601822 intermediate-risk neuroblastoma 0.586941 International Neuroblastoma Pathology 0.642606 childhood neuroblastoma 0.512977 Abstract 0.706617 Clin Oncol 0.827663 low-risk neuroblastoma group 0.586425 Neuroblastoma Susceptibility Locus 0.517512 heterogeneous MYCN-amplified neuroblastoma 0.505216 neuroblastoma oncogene 0.499459 metastatic neuroblastoma 0.519613 oncology group 0.651154	CLICK HERE
1515	National Cancer Institute	Html	en	Breast Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of ductal carcinoma in situ and invasive breast cancer.	receptor positive breast 0.389112 recurrent breast cancer 0.41257 lymph node dissection 0.398428 body 0.421534 chemotherapy 0.384234 cyclin-dependent kinase inhibitor 0.375792 PDQ cancer information 0.374498 clinical trial search 0.376459 clinical trials 0.55567 lymph nodes 0.532453 breast cancer stage 0.396227 nearby lymph nodes 0.381968 clinical trial 0.460837 breast cancer prevention 0.382905 operable breast cancer 0.404481 lymph node biopsy 0.424733 sentinel lymph node 0.494651 negative breast cancer 0.393225 hormone receptor 0.507216 Breast Cancer section 0.382102 early localized breast 0.377075 metastatic breast cancer 0.529763 radiation therapy 0.516142 invasive breast cancer 0.40061	treatment 0.558809 cancer cells 0.554268 locoregional recurrent breast 0.376998 National Cancer Institute 0.382174 Breast Cancer Treatment 0.421137 hormone therapy 0.437437 positive breast cancer 0.437025 aromatase inhibitor therapy 0.411893 lymph vessels 0.386711 breast cancer cells 0.399587 breast cancer risk 0.404406 therapy 0.540165 breast cancer 0.932332 Hereditary breast cancer 0.400558 chest wall 0.386382 IIIC breast cancer 0.390142 Male Breast Cancer 0.401114 inflammatory breast cancer 0.490531 cancer clinical trials 0.394625 lymph node 0.49671 tumor 0.424316 treatment options 0.395579 information 0.445448 surgery 0.409957	CLICK HERE
1619	National Cancer Institute	Html	en	Myelodysplastic Syndromes Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of myelodysplastic syndromes.	red blood cells 0.802655 Refractory anemia 0.210859 blast cells 0.213085 Myelodysplastic Syndromes Treatment 0.239976 blood cell transfusions 0.307965 PDQ cancer information 0.304981 Unclassifiable myelodysplastic syndrome 0.209687 white blood cells 0.599485 clinical trials 0.691716 mature blood cells 0.325517 cancer information summary 0.254688 clinical trial 0.37019 stem cell transplant 0.265266 Myeloid Leukemia Treatment 0.221437 patients 0.297669 blood cells 0.986637 standard treatment options 0.223147 immature cells 0.246396 treatment clinical trial 0.20763 NCI PDQ cancer 0.209619 myeloid stem cell 0.236773 myelodysplastic syndromes 0.714537 Treatment Editorial Board 0.221924 myeloid leukemia 0.323359 treatment 0.452708	stored stem cells 0.24091 abnormal cells 0.215174 immature blood cells 0.334065 blood stem cell 0.228491 cancer cells 0.239385 red blood cell 0.3261 acute myeloid leukemia 0.321377 patient 0.220132 treatment clinical trials 0.243695 blood stem cells 0.332989 National Cancer Institute 0.321589 blood-forming cells 0.209811 normal cells 0.213656 new treatment 0.246717 white blood cell 0.22258 bone marrow 0.630405 PDQ summary 0.205839 healthy blood cells 0.295483 cancer clinical trials 0.225848 live cells 0.215292 treatment options 0.241153 cancer 0.381961 standard treatment 0.271336 myelodysplastic syndrome 0.394764	CLICK HERE
1764	National Cancer Institute	Html	en	Tea and Cancer Prevention	A fact sheet that summarizes the results of studies about tea and cancer prevention. Includes information about the ingredients of tea and safety considerations regarding tea consumption.	tea polyphenol levels 0.386589 Green tea intake 0.401876 oolong tea 0.430327 green tea extract 0.434777 green tea catechin 0.434487 mixed tea product 0.390858 green tea infusions 0.469418 Black tea accounts 0.426082 tea catechin group 0.406391 Tea polyphenol intake 0.383146 black tea consumption 0.458652 tea varies 0.383038 tea extract supplement 0.379754 tea bags 0.400306 particular tea beverage 0.399275 green tea polyphenol 0.422956 black tea group 0.40375 tea consumption 0.652621 tea products 0.407804 green tea consumption 0.479322 different green tea 0.428697 black tea 0.677083 S. Green tea 0.391643 tea leaves 0.426385 brewed tea 0.399059	N. Tea polyphenols 0.413159 white tea 0.407798 tea solids 0.391896 green tea supplement 0.413231 common tea 0.402087 hot tea 0.38785 tea drinking 0.433775 black tea drinking 0.402834 green tea supplements 0.453812 tea plants 0.38252 green tea 0.980769 X. Green tea 0.398746 instant tea mixes 0.411097 green tea drinking 0.395736 R. Green tea 0.399438 tea polyphenols 0.638268 green tea catechins 0.51662 green tea polyphenols 0.515146 popular tea 0.402474 et al 0.644372 cancer risk 0.405162 green tea extracts 0.454939 cancer 0.441469 drinking tea 0.381909	CLICK HERE
1780	National Cancer Institute	Html	es	Tensión postraumática relacionada con el cáncer (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de la tensión postraumática y síntomas relacionados en los pacientes con cáncer, sobrevivientes del cáncer y miembros de la familia. Se discuten la evaluación y tratamiento de estos síntomas.	Coping with 0.312113 symptoms after 0.319304 Traumatic Stress Studies 0.314051 MOPP alternating with 0.310501 Trauma Stress 0.351142 Nerv Ment Dis 0.328654 Cella DF 0.451191 Arch Gen Psychiatry 0.346852 Leukemia Group B 0.316545 Post-traumatic stress after 0.328039 stress after childhood 0.327952 alternating with abvd 0.310501 Jacobsen PB 0.352264 Acute stress 0.312113 patients following autologous 0.318583 among holocaust survivors 0.314603 combat-related posttraumatic stress 0.348262 mental disorders 0.366349 criterio diagnóstico 0.338544 Green BL 0.343463 Human Stress 0.337499 traumatic stress symptoms 0.314194 cooperative clinical trials 0.320094 Hosp Community Psychiatry 0.312333 childhood cancer 0.324585	síntomas específicos tpt 0.311452 Widows MR 0.315755 tensión postraumática ttpt 0.310392 Grace MC 0.31562 Structured Clinical Interview 0.330114 postdisaster psychiatric disorders 0.311579 American Psychiatric Association 0.427992 bone marrow transplantation 0.440615 Cordova MJ 0.331735 posttraumatic stress 0.9934 Consult Clin Psychol 0.37836 life assessment 0.310879 Lindy JD 0.315479 marrow transplant recipients 0.310103 Event Scale 0.315869 Abnorm Psychol 0.310829 Kornblith AB 0.369198 Statistical Manual 0.340058 symptoms after treatment 0.312687 Anderson J 0.350583 stress symptoms 0.322303 Andrykowski MA 0.321927 post-traumatic stress 0.369384 after burn 0.311819	CLICK HERE
1976	National Cancer Institute	Html	es	Tratamiento del cáncer de seno paranasal y de cavidad nasal (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de seno paranasal y de cavidad nasal.	glándula tiroides 0.30201 Neck Cancer 0.300319 siguientes procedimientos 0.303848 pequeño número 0.300609 siguientes aspectos 0.300986 estadio ii 0.30355 senos paranasales esfenoideos 0.304208 siguientes especialistas 0.300629 aire circula 0.300623 rayos x 0.300535 pequeñas marcas 0.300312 estadio ivc 0.301666 enlace drugs approved 0.300597 seno paranasal 0.995188 dientes flojos 0.300615 nasal envía señales 0.304954	dentaduras postizas 0.300692 National Cancer Institute 0.300148 tumores benignos 0.300663 siguientes riesgos 0.300156 fraccionamiento.ampliar radioterapia 0.301581 Instituto Nacional 0.300695 malla ayuda 0.300318 PDQ Tratamiento 0.300448 Physician Data Query 0.300682 siguientes sitios 0.301656 ganglio linfático mide 0.30303 aparato respiratorio ayuda 0.301084 siguientes enlaces 0.300254 senos paranasales etmoideos 0.307274 siguientes pruebas 0.30092	CLICK HERE
1982	National Cancer Institute	Html	es	Tratamiento del cáncer de tiroides (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de tiroides.	glándula tiroides 0.908295 estadios iva 0.233602 siguientes procedimientos 0.206098 ganglios linfáticos.ampliar cáncer 0.716308 hormona tiroidea 0.292738 radioterapia intraoperatoria 0.215525 siguientes aspectos 0.243621 menos.ampliar cáncer 0.315655 gen ret 0.208945 estadio ii 0.465746 enfermedad tiroidea 0.223963 ganglio linfático centinela 0.278708 vía oral 0.205075 rayos x 0.221349 estadio ivb 0.462997 estadio ivc 0.408027 enlace drugs approved 0.226007 ondas sonoras 0.222594 estadio iva 0.373015 órgano fonador 0.446375 National Cancer Institute 0.204974	tiroides causa efectos 0.252932 endocrina múltiple tipo 0.287058 hormonas tiroideas 0.209751 Instituto Nacional 0.209158 PDQ Tratamiento 0.229219 antecedentes familiares 0.2071 pacientes pastillas 0.209381 siguientes funciones 0.210244 Physician Data Query 0.218087 estadio iii 0.401226 centímetros.ampliar cáncer 0.275936 suficiente hormona tiroidea 0.209562 nódulo tiroideo 0.292185 Thyroid Cancer 0.21393 hormona calcitonina 0.209835 pequeña dosis 0.204395 pequeña parte 0.2042 células tiroideas 0.225287 cuerpo.ampliar cáncer 0.277585 nódulos tiroideos 0.301973 tiroides.ampliar cáncer 0.26979	CLICK HERE
3854	National Cancer Institute	Html	en	With Immunotherapy, Glimmers of Progress against Glioblastoma	Researchers who specialize in brain cancer are optimistic about immunotherapy’s prospects for improving outcomes in patients with this aggressive form of brain cancer.	small trial testing 0.468005 Dr. Gilbert 0.515178 tumor-specific immune response 0.48073 malignant brain tumor 0.510587 early-phase trial testing 0.467191 dendritic cells 0.61475 operable glioblastoma 0.578819 specialized endothelial cells 0.558383 dendritic cell vaccines 0.48246 clinical trials 0.590613 glioblastoma cells 0.815515 12-patient clinical trial 0.463613 so-called peptide vaccine 0.471528 immature immune cells 0.5807 patients 0.746073 brain cancer 0.489359 healthy brain cells 0.678016 immune-based treatments 0.561628 CAR T-cell therapy 0.537367 glioblastoma 0.965748 brain tumor immunotherapy 0.646246 contractile cells 0.490726 EGFRvIII-positive glioblastoma 0.583166 checkpoint inhibitors 0.623905 glioblastoma patients 0.63769	CAR T cells 0.567214 Dr. Sampson 0.590733 advanced glioblastoma 0.567342 delivery cancer treatments 0.470619 trial testing 0.590548 immune response 0.549878 Dr. Lim 0.552388 tumor cells 0.483775 small randomized trial 0.471443 advanced melanoma 0.473209 immune cells 0.646076 trial testing rindopepimut 0.489783 Comprehensive Cancer Center 0.46874 CMV-infected cells 0.470459 newly diagnosed glioblastoma 0.754821 early-stage clinical trials 0.589931 engineering cells 0.471397 tumor immunotherapy program 0.633115 cells 0.839043 dendritic cell vaccine 0.705918 phase I/II trial 0.478298 larger randomized trials 0.595338 cancer 0.501031 glioblastoma tumors 0.562465	CLICK HERE
16715	National Cancer Institute	Html	en	Combining Targeted Therapies for Newly Diagnosed Metastatic Lung Cancer	Combining Targeted Therapies for Newly Diagnosed Metastatic Lung Cancer	different ways 0.50113 Afatinib Plus 0.525864 eligibility criteria 0.492811 cell growth 0.50521 M.D. 0.417708 Sarah B. Goldberg 0.619079 type 0.417261 toll 0.416537 lung cancer 0.900682 EGFR mutation-positive NSCLC 0.628765 Dr. Goldberg 0.509247 number 0.416777 EGFR inhibition 0.527024 mutations 0.419167 EGFR mutation-positive lung 0.62129 options 0.416767 combination 0.446178 clinical trial 0.506998 biomarkers 0.422468 response rate 0.492762 non-small cell lung 0.848673 protocol summary 0.517559 doctors 0.434669 EGFR inhibitors 0.527253 Erbitux®). 0.503443	FDA 0.432101 Advanced 0.418987 activity 0.417451 trial contact information 0.578358 EGFR Mutation-Positive Non-Small 0.656886 Drug Administration 0.495801 Phase II/III Trial 0.629587 Cetuximab Versus Afatinib 0.627245 Treatment-Naïve Patients 0.528367 investigator 0.417034 Dr. Sarah Goldberg 0.592518 EGFR protein 0.691134 trial’s principal 0.499034 first-line therapy 0.500906 cases 0.434794 Yale Cancer Center 0.605937 drugs 0.462999 progression-free survival 0.494968 EGFR inhibitor afatinib 0.642732 People 0.417276 tissue samples 0.494918 NCI Contact Center 0.571627 cell lung cancer 0.812241 time 0.416723	CLICK HERE
17241	National Cancer Institute	Html	en	Access to the National Cryo-Electron Microscopy Facility	The National Cryo-EM Facility (NCEF) at NCI provides researchers access to the latest technology for high resolution imaging. Find information on how to request access to NCEF.	projects 0.262945 initial aim 0.401771 dry shipper 0.375366 applicants 0.278558 nih.gov 0.261021 image quality control 0.517371 box inventory sheet 0.522912 Sample Information Form 0.882253 cancer research 0.726173 Frozen cryo-EM grids 0.745547 required quality 0.409244 detailed instructions 0.379914 Pre-screening image requirements 0.61579 National Cancer Institute 0.526223 SIF submission 0.480563 toxic material 0.39336 data acquisition 0.37918 BSL 0.239685 following requirements 0.388078 return shipping label 0.525705 cryo-EM images 0.589645 NIH grant holders 0.548401 NCEF Sample Information 0.614427	high resolution 0.408172 Frederick National Laboratory 0.514782 Cryo-EM pre-screening images 0.784097 imaging checklist 0.398451 National Cryo-Electron Microscopy 0.620277 Globus endpoint 0.399172 specimens 0.23265 biosafety level 0.398756 NCEF Process Workflow 0.581846 background information 0.370997 samples 0.259275 applicant 0.236116 48-hour imaging session 0.946143 state-of-the-art instruments 0.409437 plunge 0.240353 NCI 0.237448 National Cryo-EM Facility 0.663027 extramural academic users 0.607095 corresponding Sample Information 0.540144 imaging session project 0.6451 project relevance 0.409189 screening electron microscope 0.530289	CLICK HERE